Your browser doesn't support javascript.
loading
In Vitro and In Vivo Properties of CUO246, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor.
Blais, Johanne; Dean, Charles R; Lapointe, Guillaume; Leeds, Jennifer A; Ma, Sylvia; Morris, Laura; Moser, Heinz E; Osborne, Colin S; Prosen, Katherine R; Richie, Daryl; Skepper, Colin; Thompson, Katherine; Vo, Jason; Yue, Qin; Rivkin, Alexey.
Afiliación
  • Blais J; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Dean CR; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Lapointe G; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Leeds JA; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Ma S; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Morris L; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Moser HE; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Osborne CS; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Prosen KR; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Richie D; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Skepper C; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Thompson K; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Vo J; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Yue Q; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • Rivkin A; Novartis Institutes for BioMedical Research, Emeryville, California, USA.
Antimicrob Agents Chemother ; 66(12): e0092122, 2022 12 20.
Article en En | MEDLINE | ID: mdl-36448795
CUO246, a novel DNA gyrase/topoisomerase IV inhibitor, is active in vitro against a broad range of Gram-positive, fastidious Gram-negative, and atypical bacterial pathogens and retains activity against quinolone-resistant strains in circulation. The frequency of selection for single step mutants of wild-type S. aureus with reduced susceptibility to CUO246 was <4.64 × 10-9 at 4× and 8× MIC and remained low when using an isogenic QRDR mutant (<5.24 × 10-9 at 4× and 8× MIC). Biochemical assays indicated that CUO246 had potent inhibitory activity against both DNA gyrase (GyrAB) and topoisomerase IV (ParCE). Furthermore, CUO246 showed rapid bactericidal activity in time-kill assays and potent in vivo efficacy against S. aureus in a neutropenic murine thigh infection model. These results suggest that CUO246 may be useful in treating infections by various causative agents of acute skin and skin structure infections, respiratory tract infections, and sexually transmitted infections.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Girasa de ADN / Topoisomerasa de ADN IV Límite: Animals Idioma: En Revista: Antimicrob Agents Chemother Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Girasa de ADN / Topoisomerasa de ADN IV Límite: Animals Idioma: En Revista: Antimicrob Agents Chemother Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos